Tag: drug-manufacturing

Teva Pharmaceutical Industries Ltd. (TEVA) is rated Hold as the stock has already rerated on an earnings recovery, while revenue still faces generic pricing pressure. The business generates solid cash flow and strong EBITDA margins, but execution on branded growth and the AUSTEDO pricing reset remain key risks.

Read note